Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)

Journal of Asthma

Volumn 52, Issue 3, 2015, Pages 289-295

  Chishimba, Livingstone ^a,b   Langridge, Philip ^b   Powell, Georgina ^b   Niven, Robert M ^a,b   Denning, David W ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Allergic lung disease; Aspergillus lung disease; Asthma; Asthma pharmacology

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ITRACONAZOLE; PREDNISOLONE; SALBUTAMOL; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT;

ADULT; AGED; ALLERGIC ASTHMA; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; BRONCHOSPASM; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HUMAN; MALE; MEDICAL NEBULIZER; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SEVERE ASTHMA WITH FUNGAL SENSITIZATION; SIDE EFFECT; SPIROMETRY; TREATMENT DURATION; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASTHMA; CLINICAL TRIAL; MIDDLE AGED; NEBULIZER;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; QUALITY OF LIFE; VORICONAZOLE;

EID: 84931026408     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2014.958853     Document Type: Article

References (33)

1. Harrison B, Stephenson P, Mohan G, Nasser S. An ongoing confidential enquiry into asthma deaths in the eastern region of the UK, 2001-2003. Prim Care Respir J 2005;14:303-313.
2. Goldacre MJ, Duncan ME, Griffith M. Death rates for asthma in English populations 1979-2007: comparison of underlying cause and all certified causes. Public Health 2012;126:386-393.
3. Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: A systematic review. BMC Pulm Med 2013;13:70.
4. Donnelly SC, McLaughlin H, Bredin CP. Period prevalence of allergic bronchopulmonary mycosis in a regional hospital outpatient population in Ireland 1985-88. Ir J Med Sci 1991;160: 288-290.
5. Eickmeier O, et al. Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease. Curr Pharm Des 2013;19:669-3678.
6. Niels Kleinkauf PEV, Maiken C, Arendrup PJD, Cuenca-Estrella M, Fraaije B, Melchers WJG, Kema GHJ, et al. European Centre for Disease Prevention and Control. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. Stockholm: European Centre for Disease Prevention and Control (ECDC); 2013.
7. Clayton DE, Busse WW. Development of allergic bronchopulmonary aspergillosis during treatment of severe asthma with systemic corticosteroids. J Allergy Clin Immunol 1981;67: 243-246.
8. Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2003;(3):CD001108.
9. Denning DW, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009;179:11-18.
10. Chishimba L, et al. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012;49: 423-433.
11. Agbetile J, Bourne M, Fairs A, Hargadon B, Desai D, Broad C, Morley J, et al. Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study). J Allergy Clin Immunol 2014;134:33-9.
12. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68: 1029-1036.
13. Skov M, Patenaude V, Lapi F, Ernst P. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002;20:127-133.
14. Monforte V, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009;28: 170-175.
15. Proesmans M, Vermeulen F, Vreys M, De Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr 2010;2010: 376287.
16. Godet C, Meurice JC, Roblot F, Kauffmann-Lacroix C, Verdaguer M, Frat JP, Cadranel J. Efficacy of nebulised liposomal amphotericin B in the attack and maintenance treatment of ABPA. Eur Respir J 2012;39:1261-1263.
17. Laoudi Y, Paolini JB, Grimfed A, Just J. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008;31:908-909.
18. Leon EE, Craig TJ. Antifungals in the treatment of allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 1999;82:511-516; quiz 516-519.
19. Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant 2002;21:1237-1241.
20. Slobbe L, Boersma E, Rijnders BJ. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008;21:855-859.
21. Hayes D Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 2010;45:1145-1148.
22. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986;146:916-918.
23. Patterson R, Greenberger PA, Harris KE. Allergic bronchopulmonary aspergillosis. Chest 2000;118:7-8.
24. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: A summary of the evidence. Eur Respir J 2006;27:615-626.
25. Levy ML, Thomas M, Small I, Pearce L, Pinnock H, Stephenson P. Summary of the 2008 BTS/SIGN British Guideline on the management of asthma. Prim Care Respir J 2009;18:S1-S16.
26. Ricketti AJ, Greenberger PA, Mintzer RA, Patterson R. Allergic bronchopulmonary aspergillosis. Arch Intern Med 1983;143: 1553-1557.
27. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-838.
28. Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest 1995;108:750-753.
29. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, Sluiter WJ, Daenen SM, de Pauw B. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997;16: 364-368.
30. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial. Clin Infect Dis 2008;46: 1401-1408.
31. Gryn J, Goldberg J, Johnson E, Siegel J, Inzerillo J. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993;16:43-46.
32. Kamalaporn H, Leung K, Nagel M, Kittanakom S, Calvieri B, Reithmeier RA, Coates AL, et al. Aerosolized liposomal amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients. Pediatr Pulmonol 2013;49: 574-80.
33. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994;34:1001-1013.